Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546 | Completed Phase 2 Results FDA Drug

• 3 other identifiers: ACT17131U1111-1260-4204PRN473-0005
• Study Type: interventional
• Target: 39
• Locations: 2 countries
• Sites: 12

Brief Summary

This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary efficacy of PRN473 in up to 40 patients with mild to moderate AD. On Day 1 (Baseline) of the Blinded Period, 2 target lesions with a difference no greater than 1 point in Total Sign Score (TSS) were randomly assigned to treatment in an intra-patient 1:1 manner, one lesion to PRN473 and the other to matching placebo. Participation took approximately 13 weeks, including up to a 5-week screening period, a 6-week treatment period, end of study assessments 1 day after last dose, and a safety follow-up phone call 2 weeks after last dose.

Conditions

Atopic Dermatitis

Outcome Measures

Primary Outcomes (10)

• Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

  An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that occurred from the time of the first IMP in the safety analysis period.

  From the first IMP administration (Day 1) up to Day 58

• Number of Participants With Potentially Clinically Significant Abnormalities (PCSA): Vital Signs

  Vital signs assessments included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate (HR), and body temperature. Criteria for PCSA: Supine SBP: ≤ 95 mmHg and decrease from baseline ≥ 20 mmHg, ≥ 160 mmHg and increase from baseline ≥ 20 mmHg; Supine DBP : ≤ 45 mmHg and decrease from baseline ≥ 10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; Orthostatic SBP: ≤ -20 mmHg; Orthostatic DBP: ≤ -10 mmHg; Supine PR: ≤ 50 beats/min and decrease from baseline ≥ 20 beats/min, ≥ 120 beats/min and increase from baseline ≥ 20 beats/min; Weight :≥ 5% decrease from baseline, ≥ 5% increase from baseline

  From the first IMP administration (Day 1) up to Day 45

• Number of Participants With PCSA in 12-Lead Electrocardiogram (ECG)

  Criteria for PCSA: HR: less than (\<) 50 beats per minute (bpm), \> 90 bpm, \> 90 bpm and increase from baseline \> = 20 bpm, \> 100 bpm; PR interval: \> 200 milliseconds (msec), \> 200 msec and increase from baseline \>= 25 %, \> 220 msec; QRS interval: greater than (\>) 110 msec, \> 110 msec and increase from baseline greater than or equal to (\>=) 25%, \> 120 msec; QT interval: \> 500 msec; QTc interval \> 450 msec; \> 480 msec, increase from baseline (30-60) msec, increase from baseline \> 60 msec.

  From the first IMP administration (Day 1) up to Day 45

• Number of Participants With PCSA: Hematology

  Criteria for PCSA: Hemoglobin (Hb) \<=115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), \>= 185 g/L (M) or \>=165 g/L (F), decrease from baseline \>= 20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: \< 100 Giga/L, \>=700 Giga/L; Neutrophils: \<1.5 Giga/L (Non-Black \[NB\]) or \<1.0 Giga/L (Black \[B\]); Lymphocytes: \> 4.0 Giga/L; Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).

  From the first IMP administration (Day 1) up to Day 45

• Number of Participants With PCSA: Electrolyte Parameters

  Criteria for PCSA: Sodium: \<=129 millimoles (mmol)/L, \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L and Chloride: \<80 mmol/L, \>115 mmol/L.

  From the first IMP administration (Day 1) up to Day 45

• Number of Participants With PCSA: Metabolic Parameters

  Criteria for PCSA: Glucose: \<=3.9 mmol/L and \< lower limit of normal range (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]); Albumin: \<=25 g/L; Creatine kinase (CK): \> 3 ULN, \> 10 ULN; C-Reactive protein: \> 2 ULN or 10 mg(milligram)/L (if ULN not provided).

  From the first IMP administration (Day 1) up to Day 45

• Number of Participants With PCSA: Renal Function Parameters

  Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L), \>=30% change from baseline, \>=100% change from baseline.

  From the first IMP administration (Day 1) up to Day 45

• Number of Participants With PCSA: Liver Function Parameters

  Liver function parameters assessments included alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, lactate dehydrogenase, total bilirubin, direct bilirubin, and gamma glutamyl transferase (GGT).

  From the first IMP administration (Day 1) up to Day 45

• Number of Participants With PCSA: Urinalysis

  Urinalysis parameters assessments included potential of Hydrogen (pH), urobilinogen, and specific gravity.

  From the first IMP administration (Day 1) up to Day 45

• Percentage of Participants With Application-Site Event During Double-Blind Period

  Grading of application-site local tolerability symptoms (burning, pruritus, and erythema) were recorded using the grading scale following each dosing during the double-blind period. Grading of application site tolerability symptoms graded from 0 (none) to 3 (severe).

  From the first IMP administration (Day 1) up to Week 2

Secondary Outcomes (1)

• Maximum Plasma Concentration (Cmax) of SAR444727

  Day 1, 4 hours post-dose; Day 15, 1 hour post-dose and Day 43, 12 hours post-dose

Study Arms (2)

SAR444727 5% BID per lesion

EXPERIMENTAL

During the double-blinded period, 2 target lesions per participant (with difference no greater than 1 point in total sign scores \[TSS\]) were randomized in 1:1 ratio to receive either SAR44727 Gel 5 percent (%) or matching placebo (i.e., each participant was treated with both SAR444727 5% BID and placebo in parallel). During open-label period, participants applied SAR444727 Gel, 5% twice daily (BID) to the all atopic dermatitis (AD)-affected areas, except the scalp, palms, soles and genitals through Days 15 to 42.

Drug: PRN473 (SAR444727)

Placebo then SAR444727 5% BID per lesion

PLACEBO COMPARATOR

Multiple topical doses of placebo for 14 days, and PRN473 (SAR444727) for 28 days

Drug: PRN473 (SAR444727); Drug: Placebo

Interventions

PRN473 (SAR444727) DRUG

White to off-white gel suspension

Placebo then SAR444727 5% BID per lesion; SAR444727 5% BID per lesion

Placebo DRUG

White to off-white gel suspension

Placebo then SAR444727 5% BID per lesion

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female adults 18 to 70 years of age (inclusive) at the time of informed consent.
• Diagnosed with mild to moderate AD.
• History of AD for at least 6 months as determined by the Investigator through patient interview.
• Stable disease for the 4 weeks prior to the screening visit with no significant flares in AD as determined by the Investigator.
• Validated Investigator Global Assessment-atopic dermatitis (vIGA-AD) score of Moderate or Mild at Screening. The vIGA-AD was evaluated for the entire body except scalp, palms, soles and genitals.
• HadAD involvement (excluding scalp, palms, soles and genitals) of at least 1.0% BSA and no more than 14.0% BSA.
• Had at least two target lesions 100 cm2 or greater with a difference no greater than 1 point in lesion TSS and at least 5 cm apart located on the trunk (excluding genitals) or upper extremities (excluding palms).
• If female, patients with child-bearing potential must have a negative pregnancy test, and agree to practice true abstinence or agree to use highly effective contraception.
• If male, agree to use a male condom and highly effective contraception with female partners of child-bearing potential.
• In good health as judged by the Investigator.

You may not qualify if:

• Patients who had failed 2 or more prior systemic treatments for AD.
• Patients who had received a live or attenuated vaccine in the last 12 weeks or intend to receive a live or attenuated vaccine during the study.
• Patients who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study.
• Has unstable AD, based on the judgement of the Investigator, or any consistent requirement for high potency topical steroids to manage AD signs or symptoms.
• Patients who had significant active systemic or localized bacterial, viral, fungal, and helminth infection in the last 30 days.
• Patients unwilling to refrain from prolonged sun exposure or use of a tanning bed or other artificial light emitting devices for 4 weeks prior to Baseline and during the study.
• Patients with other skin conditions that would interfere with evaluations of the effect of the study medication on AD, as determined by the Investigator.
• Patients with known genetic dermatological conditions that overlap with AD, such as Netherton syndrome.
• Previous used of a BTK inhibitor.
• Women who were pregnant, wishing to become pregnant during the study, or were breastfeeding.
• Patients were undergoing allergy (eg, food allergy testing or skin prick testing), patch testing, or food challenges, or plan to do so during the study.
• Patients who had undergone major surgery within 4 weeks prior to Day 1 or patients who had a major surgery planned during the study.
• Regular use of drugs of abuse or regular alcohol consumption within 6 months prior to the study.

Sponsors & Collaborators

• Principia Biopharma, a Sanofi Company: lead

Study Sites (12)

Collaborative Neuroscience Research-Site Number:8400004

Long Beach, California, 90806, United States

Location

California Allergy & Asthma Medical Group-Site Number:8400008

Los Angeles, California, 90025, United States

Location

Florida International Research Center-Site Number:8400017

Miami, Florida, 33173, United States

Location

Lenus Research & Medical Group-Site Number:8400006

Sweetwater, Florida, 33172, United States

Location

Clinical Research Trials of Florida, Inc-Site Number:8400013

Tampa, Florida, 33607, United States

Location

Remington Davis Inc-Site Number:8400012

Columbus, Ohio, 43215, United States

Location

J&S Studies-Site Number:8400015

Bryan, Texas, 77802, United States

Location

Center for Clinical Studies, LTD. LLP-Site Number:8400014

Houston, Texas, 77004, United States

Location

Progressive Clinical Research-Site Number:8400002

San Antonio, Texas, 78213, United States

Location

Investigational Site Number :1240008

Hamilton, Ontario, L8L 3C3, Canada

Location

Investigational Site Number :1240007

London, Ontario, N6H 5L5, Canada

Location

Investigational Site Number :1240002

Québec, G1G 3Y8, Canada

Location

Related Links

• ACT17131 Plain Language Results Summary

MeSH Terms

Conditions

Dermatitis, Atopic

Interventions

PRN473

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Results Point of Contact

• Title: Trial Transparency Team
• Organization: Sanofi aventis recherche & développement

Contact-US@sanofi.com

800-633-1610

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2021
• First Posted: August 5, 2021
• Study Start: August 13, 2021
• Primary Completion: December 28, 2022
• Study Completion: December 28, 2022
• Last Updated: September 10, 2025
• Results First Posted: March 1, 2024

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

US (9); CA (3)